Attached files

file filename
EX-99.1 - EXHIBIT 99.1 - Lipocine Inc.v367690_ex99-1.htm
EX-99.2 - EXHIBIT 99.2 - Lipocine Inc.v367690_ex99-2.htm

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934

 

Date of Report (Date of Earliest Event Reported):

February 10, 2014

 

 

LIPOCINE INC.

(Exact name of registrant as specified in its charter)

 

Commission File No. 000-55092

 

Delaware   99-0370688
(State or other jurisdiction
of incorporation)
  (IRS Employer
Identification Number)

 

675 Arapeen Drive, Suite 202

Salt Lake City, Utah 84108

(Address of principal executive offices)(Zip Code)

 

Registrant’s telephone number, including area code: (801) 994-7383

 

Former name or former address, if changed since last report: Not Applicable

 

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 
 

 

Item 7.01Regulation FD Disclosure

 

The Company is presenting at the Leerink Global Healthcare Conference to be held February 12-13, 2014. Additionally before and during the conference, the Company will be meeting with investors and presenting materials to investors regarding the Company. The Company’s materials to be used in the presentations and investor meetings are attached hereto as Exhibit 99.2.

 

Item 8.01Other Events

 

On February 10, 2014, Lipocine Inc. issued a press release to report the first patient dosed in its Phase 3 Study for Oral Testosterone Replacement Therapy ("SOAR") clinical trial. The press release is furnished as Exhibit 99.1 and is incorporated herein by reference.

 

Item 9.01Financial Statements and Exhibits.

 

(d)Exhibits

 

The following exhibits are furnished with this report:

 

Exhibit No.   Description
     
99.1   Press Release Announcing First Patient Dosed in Phase 3 Study for Oral Testosterone Replacement Therapy
     
99.2   Company Presentation

 

 
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

      LIPOCINE INC.
         
Date: February 10, 2014   By: /s/ Mahesh V. Patel
        Mahesh V. Patel
        President and Chief Executive Officer